NIH P01: Prostate Cancer Bone Metastasis: Biology and Targeting
Models for Predicting PCa Progression (MPPP)
Daqing Wu, Ph.D.
Assistant
Professor
Molecular Urology and Therapeutics Program
Department of Urology
Contact Information
Department of Urology
Emory University School of Medicine
Clinic B, Suite 5111
1365 Clifton Road, N.E.
Atlanta, GA 30322
Phone: 404-778-4583
Fax: 404-778-3965
Email: dwu2@emory.edu
Education
PhD, Peking University, Beijing,
China, 1998, Biochemistry
M.S., Shandong University, Jinan, China, 1995 Microbiology
B.S., Nanjing University, Nanjing, China, 1990, Biochemistry
Research Interests
Dr. Daqing Wu’s interests focus on elucidating and targeting the aberrant signal transduction pathways implicated in human prostate cancer bone metastasis. His research has identified several important mechanisms involved in epithelial-to-mesenchymal transition, tumor-microenvironment interaction and prostate cancer organ-specific tropism. Therapeutic targeting of these pathways to retard prostate cancer bone metastasis, particularly with small-molecular drugs and monoclonal antibodies, is emphasized. Dr. Wu also devotes his efforts to the development of non-invasive imaging techniques for the detection of tumor growth and metastasis.
Selected Publications
Seo S, Gera L, Zhau HE, Qian W, Iqbal S, Johnson NA, Zhang S, Zayzafoon M, Stewart J, Wang R, Chung LWK, Wu D. BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis. Clinical Cancer Research, 14(19):6198-206, 2008.
Wu D, Zhau HE, Huang W-C, Iqbal S, Habib FK, Sartor O, Cvitananovic L, Marshall FF, Xu Z, Chung LWK. cAMP-response element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene, 26, 5070-5077, 2007.
Nomura T, Huang W-C, Zhau HE, Wu D, Xie Z, Mimata H, Zayzafoon M, Young AN, Marshall FF, Weitzmann MN, Chung LWK. ß2-Microglobulin Promotes the Growth of Human Renal Cell Carcinoma through the activation of the protein kinase A, cyclic AMP–responsive element-binding protein, and vascular endothelial growth factor axis. Clinical Cancer Research, 12, 7294-7305, 2006.
Huang W-C, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, Pohl J, Hsieh C-L, Weitzmann MN, Farach-Carson MC, Chung LWK. ß2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Research, 66, 9108-9116, 2006.
Chung LWK, Hunag W-C, Sung S-Y, Wu D, Odero-Marah V, Nomura T, Shigemura K, Miyagi T, Seo S, Shi C, Molitierno J, Elmore J, Anderson C, Isotani S, Edlund M, Hsieh C-L, Wang R, Shehata B, Zhau HE. Stromal-epithelial interaction in prostate cancer progression. Clinical Genitourinary Cancer, 5: 162-170, 2006
Wu D, Thakore CU, Wescott GG, McCubrey JA, and Terrian DM. Integrin signaling links protein kinase C-epsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene, 23: 8659-8672, 2004.
McJilton MA, Van Sikes C, Wescott GG, Wu D, Foreman TL, Gregory CW, Weidner DA, Mohler JL, Ford OH, Lasater AM, and Terrian DM. Protein kinase C-epsilon interacts with Bax and blocks the mitochondrial death signaling pathway in human prostate cancer cells. Oncogene, 22: 7958-7968, 2003.
Wu D, and Terrian DM. Regulation of caveolin-1 expression and secretion by a protein kinase C-epsilon signaling pathway in human prostate cancer cells. Journal of Biological Chemistry, 277: 40449-40455, 2002.
Wu D, Tonia L. Forman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, Alvey RF, Mohler JL, and Terrian DM. Protein kinase C-epsilon has the potential to advance the recurrence of human prostate cancer. Cancer Research, 62: 2423-2429, 2002.